[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glomerular-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glomerular-diseases":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100282275",false,"NCT02954419","IgA Nephropathy Biomarkers Evaluation Study (INTEREST)","INTEREST","Inclusion Criteria:\n\n* Male or female individuals aged 14 years or older\n* Patients with biopsy-proven primary IgA nephropathy\n* A renal biopsy available for reviewing must include 10 or more glomeruli.\n* The first renal biopsy was performed within 3 years.\n* eGFR ≥ 60 ml\u002Fmin\u002F1.73 m2 (MDRD formula);\n* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;\n* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.","ALL","14 Years",{"count":18,"type":19},2000,"ESTIMATED","OBSERVATIONAL","This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml\u002Fmin\u002F1.73 m2).",[23,24],"IgA Nephropathy","Glomerular Diseases",[23,26],"Biomarker","RECRUITING","2026-04-08",{"date":30,"type":31},"2026-04-13","ACTUAL",{"date":33,"type":4},"2016-11",{"date":35,"type":19},"2027-01",{"name":37,"class":38},"Sun Yat-sen University","OTHER",1,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":39},"100503750","NCT05839314","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy","Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled Study","Inclusion Criteria:\n\n* Renal biopsy was performed before randomization and pathologically diagnosed as idiopathic membranous nephropathy;\n* Anti-phospholipase a2 receptor (PLA2R) antibody is positive;\n* Aged from 18 to 75, either sex;\n* Tolerable doses of RASI were received for ≥4 weeks before randomization, nephrotic syndrome was not in remission and 24-hour urinary protein level was ≥3.5g\u002F24h and \\\u003C 8.0g\u002F24h;\n* The eGFR≥45ml\u002Fmin\u002F1.73m2 (Measured at least twice in 2 weeks);\n* The patient is willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Diagnosed as secondary membranous nephropathy;\n* Rapidly progressive membranous nephropathy (eGFR decreased by 50 % compared with the baseline level within 3 months);\n* Receiving renal replacement therapy;\n* Diabetes and glycosylated hemoglobin (HbA1c) levels ≥ 7.0%;\n* Hypertension is not well controlled (systolic blood pressure\\>160mmHg or diastolic blood pressure\\>100mmHg);\n* The level of serum albumin≤20g\u002FL;\n* Resistance to treatment with CsA or other CNI, rituximab (RTX) or alkylating agents; complete remission or partial remission was obtained after treatment with CNI, RTX, or alkylating agents but there was a history of relapse within 3 months；\n* Suspected infection by imaging and\u002For laboratory tests;\n* Infectious diseases, such as hepatitis B, hepatitis C, AIDS, tuberculosis;\n* History of malignant tumor;\n* Hepatic dysfunction: aspartate aminotransferase (AST) concentration and alanine aminotransferase (ALT) concentration of \\> 1.5 × upper limit of normal;\n* Allergic to Huaier granule or Ciclosporin soft capsules;\n* Previous CNI treatment was ineffective;\n* Complicate with any diseases that may affect efficacy and safety evaluation;\n* Pregnant or lactating women, and patients (male or female) with fertility plans or unwilling to take effective contraceptive measures;\n* Participating in other clinical trials or participated in other clinical studies within 3 months;\n* According to the researchers, patients have diseases or conditions that increase the difficulty of enrollment or probability of loss to follow-up, such as mental illness, frequent changes in residence and work, etc.","18 Years","75 Years",{"count":49,"type":19},480,"INTERVENTIONAL",[52],"PHASE4","This is a prospective, multicenter, randomized, open-label, parallel controlled study. The purpose of this study is to evaluate the efficacy and safety of Huaier granule on the treatment of idiopathic membranous nephropathy comparing with Ciclosporin soft capsules.",[55,24,56],"Nephropathy","Idiopathic Membranous Nephropathy",[58,59,60],"Huaier granule","Ciclosporin","Idiopathic membranous nephropathy","2024-06-02",{"date":63,"type":31},"2024-06-04",{"date":65,"type":31},"2023-05-09",{"date":67,"type":19},"2027-07-01",{"name":69,"class":38},"Chinese PLA General Hospital",""]